Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer
In 187 Chilean gallbladder cancers stained with breast cancer rules, about one in eight overexpressed HER2, one in five was borderline, and the HER2-positive patients did slightly worse, an early argument for HER2 drugs in this disease.
Overview
187 patients with gallbladder cancer (165 women, 22 men) with at least five years of follow-up and 75 controls were studied with an automated immunohistochemical technique using an anti-ErbB2 antibody, scored by the CAP/ASCO criteria for breast cancer.
Overexpression of HER2/neu was observed in 12.8% of cases (0% mucosal, 14.3% muscular, 12.8% subserosal and 10.6% serosal tumours) and equivocal staining in 20%. Overexpression was more frequent in advanced and in better-differentiated tumours (13.8% and 17.4%), not significantly. Patients with overexpression had worse five-year survival than those without (34% versus 41%). The authors concluded that overexpression occurred in 14% of advanced cases and that this subgroup might benefit from HER2 pathway inhibitors.
- HER2 overexpression in 12.8% of 187 Chilean gallbladder cancers; equivocal staining in 20%.
- Overexpression absent in mucosal tumours, 14.3% in muscular, 12.8% in subserosal, 10.6% in serosal.
- Five-year survival 34% with overexpression versus 41% without.
The largest Chilean HER2 series and the reason HER2 rates in the highest-incidence country are quoted at around 13%; scoring by breast rather than gastric rules explains part of the gap to the Japanese 31%.
- Immunohistochemistry only, no in situ hybridisation, so the 20% equivocal group is unresolved.
- No DOI; PubMed record only.
Similar pages
not linked directly; found by shared links- Key paperDetails of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), Immunohistochemistry (IHC), HER2, Gallbladder cancer.
- Key paperHER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140 cases
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), Immunohistochemistry (IHC), HER2, Gallbladder cancer.
- Key paperClinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.
- Key paperClinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy
- Key paperImmune microenvironment in gallbladder adenocarcinomas
- Key paperHER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: Concordance between immunohistochemistry and chromogenic in situ hybridization in 140 Cases
Shares Immunohistochemistry (IHC), HER2, Gallbladder cancer.
- Key paperCirculating tumor DNA profiling of advanced biliary tract cancers
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2, Gallbladder cancer.
- BiomarkerHER2 IHC 2+ (equivocal, reflex to ISH)
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), Immunohistochemistry (IHC), HER2, Gallbladder cancer.